From Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer:

Merger puzzle piece stock photo

Merger puzzle piece stock photo—

Photo credit: Depositphotos

Underwriters and Partners

Xconomy Insight

From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Key indicators & expert insight from industry leaders
Xconomy

From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities

From Our Editors · Special Report
Containing Coronavirus Through Innovation and Investment
Top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the worldwide pandemic

Xconomy on Demand

We offer a number of ways to subscribe for free!